Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4506 On Other Exchanges
Symbol
Exchange
4506 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sumitomo dainippon pharma co (4506) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUMITOMO DAINIPPON PHARMA CO (4506)

Related News

No related news articles were found.

sumitomo dainippon pharma co (4506) Related Businessweek News

No Related Businessweek News Found

sumitomo dainippon pharma co (4506) Details

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others in Japan, China, North America, and other regions. The company offers pharmaceutical products, such as therapeutic agents for hypertension, angina pectoris, arrhythmia, Parkinson’s disease, systemic fungal infections, and hepatocellular carcinoma; atypical antipsychotics; antidepressants; rapid-acting insulin secretagogues; vasodilators; and biguanide oral hypoglycemic drugs. It also provides products for therapeutic indications, such as Anderson-Fabry disease, anti-hypertension, gastroprokines, carbapenem antibiotics, sedative hypnotics, short-acting and long-acting beta-agonist, inhaled corticosteroid, corticosteroid nasal spray, and serotonin-agonist antianxiety drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, seasonings, and sweeteners; and chemical product materials, such as cosmetic and coating materials, active pharmaceutical ingredients, and electronic chemicals. Further, it offers veterinary medicines for companion animals, including dogs and cats; and farm animals, such as cattle, swine, horses, and cultured fish. Additionally, the company develops point-of-care testing diagnostic products for infectious diseases and acute myocardial infarctions; in-vitro diagnostics for bone and calcium metabolism, and central nervous system disorders; research materials that facilitate research related to medical care; and BBI608 and BBI503 anticancer drug candidates. It has a joint development agreement with Healios K.K. to develop iPS cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration and other eye diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. The company was founded in 1897 and is headquartered in Osaka, Japan.

7,015 Employees
Last Reported Date: 06/19/14
Founded in 1897

sumitomo dainippon pharma co (4506) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sumitomo dainippon pharma co (4506) Key Developments

Sumitomo Dainippon Pharma Co., Ltd. Makes Follow-Up Announcement on Preliminary Findings from Phase III Clinical Study of Lurasidone

Sumitomo Dainippon Pharma Co., Ltd. made a follow-up announcement on the preliminary findings from a Phase III clinical study (PASTEL study) conducted for application for approval in Japan of lurasidone hydrochloride, an atypical antipsychotic in the treatment of patients with schizophrenia. A close analysis has shown some differences, from the preliminary findings. A Phase III clinical study conducted for application for approval of production and distribution of lurasidone for the treatment of patients with bipolar disorder in Japan will be continued as planned. By pre-specified analysis in modified ITT population (n=439), improvements were demonstrated both for lurasidone 40 mg/day group (-17.9) and 80 mg/day group (-17.3) compared to the placebo group (-13.1) in the primary endpoint, namely, the change from baseline of the PANSS total score after 6 weeks of administration. In neither group, however, the difference was statistically significant. At the same time, by additional analysis in the ITT population (n=450), statistically significant improvements were demonstrated for lurasidone 40 mg/day (-17.7) and lurasidone 80 mg/day (-16.8) groups compared to the placebo group (-11.9) in the primary endpoint, namely, the change from baseline of the PANSS total score after 6 weeks of administration.

Sumitomo Dainippon Pharma Co., Ltd. Announces Personnel Changes, Effective April 1, 2015

Sumitomo Dainippon Pharma Co., Ltd. announced the appointment of Tsukasa Kiriyama, whose current position is Director, Oncology Clinical Development Unit, to the position of Senior Advisor, Drug Development as of April 1, 2015. The company also announced the following personnel changes to its Sales & Marketing (Division). The company appointed Kazushige Oba, whose current position is Director, Osaka Branch II, Nishi-Nippon Region, to the position of Director, Kobe Branch, Nishi-Nippon Region, and Haruo Kusakabe, whose current position is Group Manager, Osaka Group II, Psychiatry Kinki-Tokai Region, Nishi-Nippon Region, to the position of Director, Osaka Branch II, Nishi-Nippon Region, effective April 1, 2015.

DKSH Signs Agreement with Sumitomo Dainippon Pharma Co., Ltd. for Antipsychotic Drug

DKSH reached an agreement with Sumitomo Dainippon Pharma Co., Ltd. for the introduction and launch of Sumitomo's lurasidone hydrochloride, an atypical antipsychotic drug, in Thailand, Singapore and Hong Kong. DKSH Business Unit Healthcare will provide marketing, sales and regulatory services as well as distribution and logistics for lurasidone hydrochloride (generic name, "lurasidone") in Thailand, Singapore and Hong Kong.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4506:JP ¥1,354.00 JPY +5.00

4506 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $18.85 USD +0.22
FUJIFILM Holdings Corp ¥4,557 JPY +21.50
GlaxoSmithKline Consumer Nigeria PLC 54.00 NGN 0.00
Pernix Therapeutics Holdings Inc $6.43 USD -0.23
Teva Pharmaceutical Industries Ltd $60.95 USD -0.98
View Industry Companies
 

Industry Analysis

4506

Industry Average

Valuation 4506 Industry Range
Price/Earnings 26.9x
Price/Sales 1.4x
Price/Book 1.2x
Price/Cash Flow 15.7x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMITOMO DAINIPPON PHARMA CO, please visit www.ds-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.